A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan (Q44791608)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 July 2008

Language	Label	Description	Also known as
English	A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan	scientific article published on 4 July 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Kazuma Ohyashiki

2

object named as

Kazuma Ohyashiki

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Keisuke Miyazawa

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Akio Urabe

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Tomoko Hata

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Shinji Nakao

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Keiya Ozawa

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Takayuki Ishikawa

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Junji Kato

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Yoichi Tatsumi

9

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Hiraku Mori

10

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Midori Kondo

11

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Junsuke Taniguchi

12

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Hiromi Tanii

13

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Lisa Rojkjaer

14

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Mitsuhiro Omine

15

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

4 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

88

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

73-81

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Secondary iron overload

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical application of deferasirox: practical patient management

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalassaemia: clinical management

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Iron Overload Disorders: Natural History, Pathogenesis, Diagnosis, and Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Iron-chelating therapy and the treatment of thalassemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LPI-labile plasma iron in iron overload

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of long-term iron-chelating therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18597054

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-008-0115-2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44791608&oldid=2206924664"